Compass Planning Associates Inc Has $988,000 Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Compass Planning Associates Inc lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 91.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,776 shares of the medical instruments supplier's stock after buying an additional 5,623 shares during the quarter. LeMaitre Vascular comprises 1.0% of Compass Planning Associates Inc's investment portfolio, making the stock its 11th largest holding. Compass Planning Associates Inc owned 0.05% of LeMaitre Vascular worth $988,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in LMAT. Congress Asset Management Co. lifted its position in shares of LeMaitre Vascular by 1.8% in the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock worth $66,555,000 after buying an additional 13,009 shares during the last quarter. Geode Capital Management LLC raised its position in shares of LeMaitre Vascular by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock valued at $50,711,000 after purchasing an additional 7,737 shares during the period. Northern Trust Corp boosted its holdings in shares of LeMaitre Vascular by 5.1% during the 4th quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock worth $30,205,000 after buying an additional 15,843 shares during the period. Price T Rowe Associates Inc. MD grew its stake in LeMaitre Vascular by 0.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock valued at $26,240,000 after buying an additional 1,680 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in LeMaitre Vascular by 7.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 259,429 shares of the medical instruments supplier's stock worth $23,904,000 after acquiring an additional 16,886 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Trading Up 0.9%

Shares of NASDAQ LMAT opened at $84.13 on Friday. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 45.97, a PEG ratio of 2.22 and a beta of 0.83. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58. The business has a fifty day simple moving average of $83.71 and a 200 day simple moving average of $91.10.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The business had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company's quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.44 EPS. On average, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were paid a $0.20 dividend. The ex-dividend date was Thursday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.95%. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 18,733 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the transaction, the chief executive officer now owns 1,873,651 shares in the company, valued at $158,829,395.27. This represents a 0.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. This represents a 26.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold 102,009 shares of company stock worth $8,721,836 in the last quarter. 9.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LMAT shares. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital increased their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, LeMaitre Vascular has an average rating of "Hold" and an average price target of $97.83.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.